Showing results (2151-2160 of 2,317) with videos related to
Sort By:
Pageof 232
The Lancet. Respiratory Medicine|June 24, 2021
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 studyShun Lu, Jian Fang, Xingya Li, et al.Oncotarget|October 7, 2015
S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot studyYu Hong Li, Miao Zhen Qiu, Jian Ming Xu, et al.The Lancet Regional Health. Western Pacific|January 6, 2025
Consensus on the lung cancer management after third-generation EGFR-TKI resistanceQing Zhou, Hongyun Zhao, Shun Lu, et al.The Lancet. Respiratory Medicine|June 2, 2020
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trialYi-Long Wu, Ying Cheng, Jianying Zhou, et al.JAMA Oncology|September 2, 2021
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical TrialLeora Horn, Ziping Wang, Gang Wu, et al.International Journal of Cancer|September 19, 2022
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysisTianshu Liu, Yuxian Bai, Xiaoyan Lin, et al.Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|April 25, 2021
[Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2020 Version)]Caicun Zhou, Jie Wang, Baocheng Wang, et al.Chinese Clinical Oncology|January 8, 2017
Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III studyLiu-Qing Yang, Xin-Chen Sun, Shu-Kui Qin, et al.Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|July 11, 2024
Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumorsJian Li, Ye Xu, Aimin Zang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 27, 2024
Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)Yuankai Shi, Jianhua Chen, Runxiang Yang, et al.Pageof 232